Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol.
about
Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Second-line treatment of recur ...... cetuximab-paclitaxel protocol.
@ast
Second-line treatment of recur ...... cetuximab-paclitaxel protocol.
@en
type
label
Second-line treatment of recur ...... cetuximab-paclitaxel protocol.
@ast
Second-line treatment of recur ...... cetuximab-paclitaxel protocol.
@en
prefLabel
Second-line treatment of recur ...... cetuximab-paclitaxel protocol.
@ast
Second-line treatment of recur ...... cetuximab-paclitaxel protocol.
@en
P2093
P2860
P1433
P1476
Second-line treatment of recur ...... cetuximab-paclitaxel protocol.
@en
P2093
P2860
P2888
P356
10.1186/S13014-016-0583-0
P577
2016-01-20T00:00:00Z
P5875
P6179
1033413701